Daunorubicin and cytarabine liposome (Intravenous)
Medically reviewed by Drugs.com. Last updated on Apr 24, 2022.
Do not interchange with other DAUNOrubicin- and/or cytarabine-containing productsDAUNOrubicin and cytarabine, liposome has different dosage recommendations than DAUNOrubicin hydrochloride injection, cytarabine injection, DAUNOrubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors .
Commonly used brand name(s)
In the U.S.
- Vyxeos
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Antimetabolite
Chemical Class: Anthracycline
Uses for daunorubicin and cytarabine liposome
Daunorubicin and cytarabine injection is used to treat therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC).
Daunorubicin and cytarabine liposome interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by doxorubicin and cytarabine liposome, other unwanted side effects will also occur. Some of these may be serious and must be reported to your doctor.
Daunorubicin and cytarabine liposome is to be given only by or under the supervision of your doctor.
Before using daunorubicin and cytarabine liposome
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For daunorubicin and cytarabine liposome, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to daunorubicin and cytarabine liposome or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of daunorubicin and cytarabine injection in children 1 year of age and older. Safety and efficacy have been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of daunorubicin and cytarabine injection in the elderly. However, elderly patients are more likely to have bleeding problems, which may require caution in patients receiving daunorubicin and cytarabine liposome.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving daunorubicin and cytarabine liposome, it is especially important that your healthcare profes..
